Quality of Life of Ghanaian Chronic Myeloid Leukaemia Patients on Tyrosine Kinase Inhibitors

被引：0
作者：
Kuma, A. Benneh-Akwasi [1 ,2 ]
Amponsah, E. [3 ]
Kyeremeh, R. [3 ]
Olayemi, E. [1 ,2 ]
机构：
[1] Univ Ghana, Haematol, Accra, Ghana
[2] Korle Bu Teaching Hosp, Accra, Ghana
[3] Univ Ghana, Med Lab Sci, Accra, Ghana
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
Chronic myeloid leukaemia; Ghana; Quality of Life; Tyrosine Kinase Inhibitor;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-PO-0
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [21] Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies
    Hewison, Ann
    Atkin, Karl
    McCaughan, Dorothy
    Roman, Eve
    Smith, Alex
    Smith, Graeme
    Howell, Debra
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2020, 45
  • [22] Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study
    Yang, Yu-Chien
    Huang, Ru-Yu
    Tsai, Hui-Jen
    Li, Po-Chih
    Yang, Yi-Hsin
    Hsieh, Kun-Pin
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (09) : 1312 - 1321
  • [23] Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study
    Kekale, Meri
    Soderlund, Tim
    Koskenvesa, Perttu
    Talvensaari, Kimmo
    Airaksinen, Marja
    JOURNAL OF ADVANCED NURSING, 2016, 72 (09) : 2196 - 2206
  • [24] Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
    Kondo, Takeshi
    Matsuki, Eri
    Takaku, Tomoiku
    Watanabe, Naoki
    Yoshida, Chikashi
    Okada, Masaya
    Murai, Kazunori
    Kodama, Takashi
    Takahashi, Naoto
    Kimura, Shinya
    Matsumura, Itaru
    CANCER, 2025, 131 (01)
  • [25] Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?
    Eskazan, Ahmet Emre
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (10) : 2241 - 2243
  • [26] Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol
    Balakumaran, Janatani
    Birk, Tanisha
    Golemiec, Breanne
    Helmeczi, Wryan
    Inkaran, Jeyanth
    Kao, Yun-ya
    Leigh, Jennifer
    Saliba, Sarah
    Sharma, Rishi
    Spatafora, Laura
    Wright, Kristin
    Yao, William
    Hillis, Christopher
    Banfield, Laura
    Thabane, Lehana
    Athale, Uma
    Samaan, M. Constantine
    BMJ OPEN, 2019, 9 (09):
  • [27] Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis
    Fachi, Mariana M.
    Tonin, Fernanda S.
    Leonart, Leticia P.
    Rotta, Inajara
    Fernandez-Llimos, Fernando
    Pontarolo, Roberto
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (10) : 2280 - 2291
  • [28] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Elisabetta Abruzzese
    Massimo Breccia
    Roberto Latagliata
    BioDrugs, 2014, 28 : 17 - 26
  • [29] Intolerance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Definitions and Clinical Implications
    Pinilla-Ibarz, Javier
    Cortes, Jorge
    Mauro, Michael J.
    CANCER, 2011, 117 (04) : 688 - 697
  • [30] Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
    Haznedaroglu, Ibrahim C.
    TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (03) : 247 - 255
12345